Please assess the completion status of the following clinical trial:

Trial Title: Melatonin Replacement Therapy in Pinealectomized Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with pinealectomy and all of the following criteria were considered for admission to the clinical trial:~* children, adolescents and young adults 0 months to 25 years of age;~* signed written informed consent (patient or his/her parents/legal guardian);~* willing and able to complete the clinical trial procedures, as described in the protocol~* no recurring tumor after pinealectomy and subsequent chemotherapy~* absence of circulating melatonin evaluated by salivary melatonin Elisa assay~Exclusion Criteria:~* patients with cardiac arrhythmias~* potentially non-compliant subjects judged by the investigator to be unsuitable for the study

- Gender: None
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Melatonin Replacement Therapy (Type: EXPERIMENTAL): Melatonin (Aché Pharmaceutics, Brazil) 3 mg, administered in the evening, 30 minutes before the usual bedtime, every day for 3 months. After discontinuation of melatonin therapy, patients are followed up for 6 months to assess safety parameters and cardiac autonomic activity.

Based on this trial design, predict the completion outcome and termination type (if applicable).